Free Trial
→ A new rule goes live in July — and the banks are quietly cashing in (From American Alternative) (Ad)
NASDAQ:ACTU

Actuate Therapeutics 9/24/2024 Earnings Report

Actuate Therapeutics logo
$5.97 -0.23 (-3.71%)
Closing price 04:00 PM Eastern
Extended Trading
$5.98 +0.01 (+0.17%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Actuate Therapeutics EPS Results

Actual EPS
-$4.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Actuate Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Actuate Therapeutics Announcement Details

Quarter
Date
9/24/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Actuate Therapeutics Earnings Headlines

Actuate Therapeutics, Inc.
June 30, 2025  |  cnn.comhttps://www.cnn.com/markets/stocks/ACTU
Actuate Therapeutics Reports Promising Survival Outcomes in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - Nasdaq
June 26, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/actuate-therapeutics-reports-promising-survival-outcomes-phase-2-trial-elraglusib
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
July 15 at 2:00 AM  |  Paradigm Press (Ad)
Myelofibrosis Market Poised for Strong Growth, Fueled by FDA Designations and Promising Clinical Outcomes | DelveInsight
June 24, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/33011944/myelofibrosis-market-poised-for-strong-growth-fueled-by-fda-designations-and-promising-clinical-outcomes-delveinsight/
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
June 24, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/24/3104339/0/en/actuate-therapeutics-highlights-significant-and-sustained-survival-benefit-in-key-metastatic-pancreatic-cancer-patient-populations-in-phase-2-elraglusib-trial.html
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
June 20, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/20/3102706/0/en/actuate-therapeutics-reports-positive-biomarker-and-machine-learning-data-from-phase-2-elraglusib-trial-in-first-line-treatment-of-metastatic-pancreatic-cancer-at-asco.html
See More Actuate Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Actuate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Actuate Therapeutics and other key companies, straight to your email.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ:ACTU), headquartered in Irvine, California, is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies targeting hormone-driven pathways and DNA damage repair mechanisms in oncology. The company leverages proprietary formulation technologies and deep scientific expertise to create treatments aimed at improving outcomes for patients with advanced cancers.

The company’s lead asset, onapristone extended release (ONA-XR), is an oral selective progesterone receptor antagonist designed to block progesterone-driven tumor growth. ONA-XR is being evaluated in multiple clinical trials, including studies in metastatic breast cancer and endometrial carcinoma. In addition to ONA-XR, Actuate is advancing a pipeline of earlier-stage programs that focus on modulating DNA damage response pathways, with the goal of addressing treatment resistance and enhancing precision therapy options.

Since its founding in 2016, Actuate Therapeutics has pursued strategic collaborations with academic institutions and clinical research sites across North America and Europe. The company’s management team, led by President and Chief Executive Officer Mark McCamish, Ph.D., brings together extensive experience in oncology drug development, regulatory strategy and commercialization planning. Actuate remains committed to translating scientific innovation into meaningful therapeutic advances for patients with high-unmet-need cancers.

View Actuate Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles